Biocon Limited has announced the commencement of its Qualified Institutions Placement (QIP) of equity shares, setting a floor price of ₹387.74 per share. The pharmaceutical company's Fund Raising Committee authorized the opening of the issue on January 12, 2026, marking a significant capital raising initiative under the regulatory framework of SEBI ICDR Regulations.

QIP Authorization and Pricing Details

The Fund Raising Committee convened on January 12, 2026, from 4:30 PM to 4:40 PM IST, and passed key resolutions for the QIP implementation. The committee's decisions were based on prior approvals obtained from the company's Board of Directors and shareholders through established governance processes.

Regulatory Approvals and Timeline

The QIP received comprehensive approvals through a structured timeline of corporate governance processes. The Board of Directors initially approved the proposal at their meeting held on December 06, 2025. Subsequently, shareholders provided their consent through a special resolution passed at the Extra-ordinary General Meeting conducted on December 31, 2025.

The Fund Raising Committee established January 12, 2026, as the 'relevant date' for the QIP under Regulation 171 of the SEBI ICDR Regulations. This date serves as the reference point for determining the floor price using the prescribed pricing formula under Regulation 176(1) of the SEBI ICDR Regulations.

Issue Structure and Pricing Flexibility

The QIP is being conducted under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and relevant sections of the Companies Act, 2013. The regulatory framework provides Biocon with pricing flexibility within defined parameters.

Pursuant to shareholder approval and SEBI regulations, the company retains discretionary authority to offer a discount of up to 5% on the established floor price. The final issue price will be determined through consultation between Biocon and the appointed book running lead managers for the placement.

Documentation and Compliance Measures

Biocon has prepared and adopted a preliminary placement document dated January 12, 2026, along with the corresponding application form for the QIP. The company will file this preliminary placement document with the stock exchanges as part of the regulatory compliance process.

In accordance with insider trading regulations, Biocon has implemented trading window restrictions for company securities. The trading window closure remains in effect until further notice, ensuring compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

Market Communication and Transparency

The announcement fulfills Biocon's disclosure obligations under Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made the QIP intimation available on its official website at www.biocon.com , ensuring transparent communication with all stakeholders.

The QIP represents Biocon's strategic approach to capital raising through qualified institutional investors, providing access to growth capital while maintaining regulatory compliance and corporate governance standards.

Biocon has received approval from the US Food and Drug Administration (USFDA) for its Everolimus tablets, marking a significant regulatory achievement for the Indian pharmaceutical company. The approval covers three different tablet strengths, providing healthcare providers with flexible dosing options for patient treatment.

Product Specifications and Strengths

The USFDA has approved Biocon's Everolimus tablets in the following specifications:

Therapeutic Applications

The approved Everolimus tablets are indicated for treating two specific medical conditions. Tuberous Sclerosis Complex represents a rare genetic disorder that causes non-malignant tumors to form in various organs throughout the body. The second indication covers Subependymal Giant Cell Astrocytomas (SEGAs), which are slow-growing brain tumors typically associated with Tuberous Sclerosis Complex.

Market Impact and Portfolio Expansion

This USFDA approval strengthens Biocon's position in the American pharmaceutical market, particularly in the oncology and rare disease segments. The multiple strength formulations provide physicians with dosing flexibility when treating patients with these specialized conditions. Everolimus belongs to a class of medications known as mTOR inhibitors, which work by blocking certain proteins that promote cell growth and division.

Regulatory Significance

Receiving USFDA approval represents a crucial milestone for pharmaceutical companies seeking to establish their presence in one of the world's largest healthcare markets. The approval process involves rigorous evaluation of safety, efficacy, and manufacturing quality standards. For Biocon, this achievement adds another product to its growing portfolio of US-approved medications and demonstrates the company's capability to meet stringent regulatory requirements for specialized therapeutic areas.